Alcon is trading sharply lower as investors digest its first-quarter 2026 report, where sales increased but reported (IFRS) profitability fell meaningfully. The results highlighted that cost headwinds—including incremental tariffs, efficiency-initiative expenses, and an intangible impairment—pressured reported operating income and EPS, which dominated the market’s read-through despite solid underlying demand in eye care.

For the quarter ended March 31, 2026, Alcon reported sales of $2.685 billion, up 10% year over year (6% in constant currency). Reported diluted EPS fell to $0.39 from $0.70 a year earlier and reported operating income declined to $292 million, while core diluted EPS rose to $0.85 and core operating margin improved to 21.2%, underscoring a wide gap between underlying performance and reported results driven by items such as tariffs, efficiency measures, and an intangible impairment.

The quarter absorbed $33 million of additional tariffs, $88 million of efficiency-initiative costs, and a $38 million intangible impairment, which weighed on reported margins and earnings. Management also flagged that the prior-year quarter benefited from investment remeasurement gains, making the year-over-year reported EPS comparison tougher and amplifying the headline decline in IFRS profitability.

Alcon maintained its 2026 outlook for 5%–7% constant-currency sales growth and core operating margin expansion, and slightly raised its constant-currency core EPS growth view to 10%–13%. The company also announced a new authorization of up to $1.5 billion of share repurchases over three years (subject to Swiss Takeover Board authorization) alongside a CHF 0.28 per-share dividend, but today’s trading indicates investors are prioritizing near-term margin and cost pressures over the longer-term capital return story.